{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T08:06:36Z","timestamp":1784707596195,"version":"3.55.0"},"reference-count":105,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.554134","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T06:56:20Z","timestamp":1600930580000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Possible Novel Therapeutic Targets in Lymphangioleiomyomatosis Treatment"],"prefix":"10.3389","volume":"7","author":[{"given":"Xixi","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev-med-050715-104245","article-title":"Lymphangioleiomyomatosis: a monogenic model of malignancy","volume":"68","author":"Krymskaya","year":"2017","journal-title":"Ann Rev Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13023-018-0874-7","article-title":"The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis","volume":"13","author":"Gao","year":"2018","journal-title":"Orphanet J Rare Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/qjmed\/hcr116","article-title":"Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis","volume":"104","author":"Harknett","year":"2011","journal-title":"QJM."},{"key":"B4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012. International tuberous sclerosis complex consensus conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatr Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2015.12.008","article-title":"Lymphangioleiomyomatosis: current understanding and potential treatments","volume":"158","author":"Moir","year":"2016","journal-title":"Pharmacol Therapeut."},{"key":"B6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1272\/jnms.67.311","article-title":"Lymphangioleiomyomatosis (LAM) a review of clinical and morphological features","volume":"67","author":"Ferrans","year":"2000","journal-title":"J Nippon Med School."},{"key":"B7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ccm.2016.04.002","article-title":"Lymphangioleiomyomatosis","volume":"37","author":"Johnson","year":"2016","journal-title":"Clin Chest Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.2147\/OTT.S161360","article-title":"Lymphangioleiomyomatosis: a case report and review of diagnosis and treatment","volume":"11","author":"Liu","year":"2018","journal-title":"OncoTargets Therapy."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.rmed.2010.05.003","article-title":"Clinical analysis of patients with pulmonary lymphangioleiomyomatosis (PLAM) in mainland China","volume":"104","author":"Ye","year":"2010","journal-title":"Respir Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1164\/rccm.201709-1965ST","article-title":"Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official American thoracic society\/Japanese respiratory society clinical practice guideline","volume":"196","author":"Gupta","year":"2017","journal-title":"Am J Resp Crit Care Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1089\/lrb.2009.0020","article-title":"mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the \u201cperfect storm\u201d of pro-metastatic factors in LAM pathogenesis","volume":"8","author":"Yu","year":"2010","journal-title":"Lymphat Res Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"16409","DOI":"10.1074\/jbc.270.27.16409","article-title":"Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific rap1GAP activity","volume":"270","author":"Wienecke","year":"1995","journal-title":"J Biol Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.molcel.2012.06.009","article-title":"TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1","volume":"47","author":"Christian","year":"2012","journal-title":"Mol Cell."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1128\/MCB.01061-10","article-title":"mTORC2 Is required for proliferation and survival of TSC2-null cells","volume":"31","author":"Goncharova","year":"2011","journal-title":"Mol Cell Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5603\/FHC.2013.001","article-title":"LAM cells biology and lymphangioleiomyomatosis","volume":"51","author":"Grzegorek","year":"2013","journal-title":"Folia Histochem Cytobiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1038\/s41598-019-39418-5","article-title":"Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells","volume":"9","author":"Valianou","year":"2019","journal-title":"Sci Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"37288","DOI":"10.1074\/jbc.M303257200","article-title":"Inactivation of the Tuberous sclerosis complex-1 and\u22122 gene products occurs by phosphoinositide 3-kinase\/Akt-dependent and -independent phosphorylation of tuberin","volume":"278","author":"Tee","year":"2003","journal-title":"J Biol Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1128\/MCB.00735-09","article-title":"Characterization of rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1","volume":"29","author":"Dibble","year":"2009","journal-title":"Mol Cell Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.cell.2011.02.014","article-title":"Activation of mTORC2 by association with the ribosome","volume":"144","author":"Zinzalla","year":"2011","journal-title":"Cell."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1038\/emboj.2010.271","article-title":"mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide","volume":"29","author":"Oh","year":"2010","journal-title":"EMBO J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"pe24","DOI":"10.1126\/scisignal.267pe24","article-title":"The pharmacology of mTOR inhibition","volume":"2","author":"Guertin","year":"2009","journal-title":"Sci Signal."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.7326\/0003-4819-154-12-201106210-00007","article-title":"Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus","volume":"154","author":"Taveira-Dasilva","year":"2011","journal-title":"Ann Intern Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.14564.1","article-title":"Recent advances in the management of lymphangioleiomyomatosis","volume":"7","author":"Xu","year":"2018","journal-title":"F1000Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.chest.2017.05.012","article-title":"Long-term effect of sirolimus on serum VEGF-D levels in patients with lymphangioleiomyomatosis","volume":"153","author":"Taveira-Dasilva","year":"2017","journal-title":"Chest"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"725","DOI":"10.4161\/auto.5.5.8504","article-title":"Rapamycin inhibits mTORC1, but not completely","volume":"5","author":"Thoreen","year":"2009","journal-title":"Autophagy."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.3390\/ijms16022641","article-title":"Autophagy in DNA damage response","volume":"16","author":"Czarny","year":"2015","journal-title":"Int J Mol Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"12455","DOI":"10.1073\/pnas.1104361108","article-title":"Tumorigenesis in tuberous sclerosis complex is autophagy and p62\/sequestosome 1 (SQSTM1)-dependent","volume":"108","author":"Parkhitko","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.4161\/auto.7.11.17652","article-title":"Autophagy","volume":"7","author":"Yu","year":"2011","journal-title":"Autophagy."},{"key":"B32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1513\/pats.200909-104JS","article-title":"Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy","volume":"7","author":"Yu","year":"2010","journal-title":"Proc Am Thoracic Soc."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.chest.2017.01.033","article-title":"Sirolimus and autophagy inhibition in lymphangioleiomyomatosis: results of a phase I clinical trial","volume":"151","author":"El-Chemaly","year":"2017","journal-title":"Chest."},{"key":"B34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4161\/cc.27355","article-title":"Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells","volume":"13","author":"Alayev","year":"2014","journal-title":"Cell Cycle."},{"key":"B35","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1165\/rcmb.2015-0022OC","article-title":"Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors","volume":"53","author":"Alayev","year":"2015","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/cancers10010018","article-title":"mTOR pathways in cancer and autophagy","volume":"10","author":"Paquette","year":"2018","journal-title":"Cancers."},{"key":"B37","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1165\/rcmb.2014-0033OC","article-title":"Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis","volume":"51","author":"Sun","year":"2014","journal-title":"Am J Resp Cell Mol Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1038\/onc.2014.295","article-title":"The role of poly (ADP-ribosyl) ation in DNA damage response and cancer chemotherapy","volume":"34","author":"Li","year":"2015","journal-title":"Oncogene."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1158\/1078-0432.CCR-15-1772","article-title":"mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer","volume":"22","author":"Mo","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2310\/6650.2001.33787","article-title":"Distribution and mRNA expression of insulin-like growth factor system in pulmonary lymphangioleiomyomatosis","volume":"49","author":"Valencia","year":"2001","journal-title":"J Invest Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1136\/thx.2006.071811","article-title":"Lymphangioleiomyomatosis\u2013presence of receptor tyrosine kinases and the angiogenesis factor VEGF-A as potential therapeutic targets","volume":"62","author":"Watz","year":"2007","journal-title":"Thorax."},{"key":"B42","doi-asserted-by":"publisher","first-page":"L1447","DOI":"10.1152\/ajplung.00262.2015","article-title":"Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis","volume":"309","author":"Atochina-Vasserman","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0002-9440(10)61198-4","article-title":"Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma","volume":"167","author":"Lesma","year":"2005","journal-title":"Am J Pathol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/315240","article-title":"Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis","volume":"2015","author":"Lesma","year":"2015","journal-title":"BioMed Res Int."},{"key":"B45","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1158\/0008-5472.CAN-06-3567","article-title":"Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth","volume":"67","author":"Laakkonen","year":"2007","journal-title":"Cancer Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1056\/NEJMc0707517","article-title":"Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis","volume":"358","author":"Young","year":"2008","journal-title":"N Engl J Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-2600(13)70090-0","article-title":"Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the multicenter international lymphangioleiomyomatosis efficacy of sirolimus (MILES) trial","volume":"1","author":"Young","year":"2013","journal-title":"Lancet Respir Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ejcb.2016.08.001","article-title":"c- Src and its role in cystic fibrosis","volume":"95","author":"Massip Copiz","year":"2016","journal-title":"Eur J Cell Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.bbrc.2004.09.171","article-title":"Src protein\u2013tyrosine kinase structure and regulation","volume":"324","author":"Roskoski","year":"2004","journal-title":"Biochem Biophys Res Commun."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1158\/0008-5472.CAN-13-1256","article-title":"Src kinase is a novel therapeutic target in lymphangioleiomyomatosis","volume":"74","author":"Tyryshkin","year":"2014","journal-title":"Cancer Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.tips.2014.05.007","article-title":"Getting Syk: spleen tyrosine kinase as a therapeutic target","volume":"35","author":"Geahlen","year":"2014","journal-title":"Trends Pharmacol Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/sj.bjc.6605763","article-title":"A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk","volume":"103","author":"Katz","year":"2010","journal-title":"Br J Cancer."},{"key":"B53","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1752-0509-7-S5-S1","article-title":"Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer","volume":"7","author":"Udyavar","year":"2013","journal-title":"BMC Syst Biol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"M\u00f3csai","year":"2010","journal-title":"Nat Rev Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1182\/blood-2006-05-026203","article-title":"Syk-dependent mTOR activation in follicular lymphoma cells","volume":"108","author":"Leseux","year":"2006","journal-title":"Blood."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1158\/0008-5472.CAN-16-2755","article-title":"Aberrant SYK kinase signaling is essential for tumorigenesis induced by TSC2 inactivation","volume":"77","author":"Cui","year":"2017","journal-title":"Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1378\/chest.117.1.25","article-title":"Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis","volume":"117","author":"Logginidou","year":"2000","journal-title":"Chest."},{"key":"B58","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00428-014-1559-9","article-title":"In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor","volume":"464","author":"Gao","year":"2014","journal-title":"Virchows Arch."},{"key":"B59","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1152\/ajplung.00204.2003","article-title":"Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways","volume":"286","author":"Yu","year":"2003","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1677\/JME-08-0103","article-title":"Non-classical genomic estrogen receptor (ER)\/specificity protein and ER\/activating protein-1 signaling pathways","volume":"41","author":"Safe","year":"2008","journal-title":"J Mol Endocrinol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"14960","DOI":"10.1073\/pnas.1309110110","article-title":"Integration of mTOR and estrogen\u2013ERK2 signaling in lymphangioleiomyomatosis pathogenesis","volume":"110","author":"Gu","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B62","doi-asserted-by":"publisher","first-page":"23114","DOI":"10.1074\/jbc.M401912200","article-title":"Estrogen-induced smooth muscle cell growth is regulated by tuberin and associated with altered activation of platelet-derived growth factor receptor-beta and ERK-1\/2","volume":"279","author":"Finlay","year":"2004","journal-title":"J Biol Chem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1073\/pnas.0810790106","article-title":"Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells","volume":"106","author":"Yu","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e1231","DOI":"10.1038\/cddis.2014.204","article-title":"Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells","volume":"5","author":"Sun","year":"2014","journal-title":"Cell Death Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1055\/s-0040-1702195","article-title":"Lymphangioleiomyomatosis","volume":"41","author":"Xu","year":"2020","journal-title":"Semin Respir Crit Care Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1513\/AnnalsATS.201610-824OC","article-title":"A phase II clinical trial of an aromatase inhibitor for postmenopausal women with lymphangioleiomyomatosis","volume":"14","author":"Lu","year":"2017","journal-title":"Ann Am Thoracic Soc."},{"key":"B67","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.bbadis.2009.12.009","article-title":"Pathological roles of MAPK signaling pathways in human diseases","volume":"1802","author":"Kim","year":"2010","journal-title":"Biochim Biophys Acta."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1039\/C5MB00101C","article-title":"The PI3K\/AKT\/mTOR interactive pathway","volume":"11","author":"Ersahin","year":"2015","journal-title":"Mol BioSyst."},{"key":"B69","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e104413","DOI":"10.1371\/journal.pone.0104413","article-title":"mTOR inhibition induces compensatory, therapeutically targetable mek activation in renal cell carcinoma","volume":"9","author":"Bailey","year":"2014","journal-title":"PLoS ONE."},{"key":"B71","doi-asserted-by":"publisher","first-page":"56698","DOI":"10.18632\/oncotarget.18082","article-title":"Inhibition of the PI3K\/AKT\/mTOR pathway activates autophagy and compensatory Ras\/Raf\/MEK\/ERK signalling in prostate cancer","volume":"8","author":"Butler","year":"2017","journal-title":"Oncotarget"},{"key":"B72","doi-asserted-by":"publisher","first-page":"7878","DOI":"10.18632\/oncotarget.13987","article-title":"Dual inhibition of the PI3K\/AKT\/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications","volume":"8","author":"Fourneaux","year":"2017","journal-title":"Oncotarget."},{"key":"B73","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/13543784.2018.1415324","article-title":"MEK inhibitors under development for treatment of non-small-cell lung cancer","volume":"27","author":"Kim","year":"2018","journal-title":"Expert Opin Invest Drugs."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1378\/chest.96.6.1352","article-title":"Treatment of lymphangioleiomyomatosis: a meta-analysis","volume":"96","author":"Eliasson","year":"1989","journal-title":"Chest."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1378\/chest.126.6.1867","article-title":"Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone","volume":"126","author":"Taveira-Dasilva","year":"2004","journal-title":"Chest."},{"key":"B76","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1164\/ajrccm.160.2.9901027","article-title":"Decline in lung function in lymphangioleiomyomatosis","volume":"160","author":"Johnson","year":"1999","journal-title":"Am J Resp Crit Care Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s12672-014-0192-z","article-title":"Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis","volume":"5","author":"Sun","year":"2014","journal-title":"Horm Cancer."},{"key":"B78","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pharmthera.2017.08.009","article-title":"EMT: mechanisms and therapeutic implications","volume":"182","author":"Singh","year":"2018","journal-title":"Pharmacol Therap."},{"key":"B79","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10585-017-9853-y","article-title":"Expression of ezrin and moesin in primary breast carcinoma and matched lymph node metastases","volume":"34","author":"Bartova","year":"2017","journal-title":"Clin Exp Meta."},{"key":"B80","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/his.12202","article-title":"Expression of moesin and CD44 is associated with poor prognosis in gastric adenocarcinoma","volume":"63","author":"Jung","year":"2013","journal-title":"Histopathology."},{"key":"B81","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12885-017-3914-0","article-title":"Moesin expression by tumor cells is an unfavorable prognostic biomarker for oral cancer","volume":"18","author":"Barros","year":"2018","journal-title":"BMC Cancer."},{"key":"B82","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s00401-002-0540-x","article-title":"Ezrin and moesin expression within the developing human cerebrum and tuberous sclerosis-associated cortical tubers","volume":"104","author":"Johnson","year":"2002","journal-title":"Acta Neuropathol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1242\/jcs.053157","article-title":"Moesin orchestrates cortical polarity of melanoma tumour cells to initiate 3D invasion","volume":"122","author":"Estecha","year":"2009","journal-title":"J Cell Sci."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1055\/s-0038-1675399","article-title":"The urokinase plasminogen activator system in human cancers: an overview of its prognostic and predictive role","volume":"118","author":"Maduni\u0107","year":"2018","journal-title":"Thromb Haemost."},{"key":"B85","doi-asserted-by":"publisher","first-page":"20528","DOI":"10.1074\/jbc.M117.799593","article-title":"Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors","volume":"292","author":"Stepanova","year":"2017","journal-title":"J Biol Chem."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr Biol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e111476","DOI":"10.1371\/journal.pone.0111476","article-title":"Tumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts","volume":"9","author":"Goncharova","year":"2014","journal-title":"PLoS ONE."},{"key":"B88","doi-asserted-by":"publisher","first-page":"9878","DOI":"10.1158\/0008-5472.CAN-07-1394","article-title":"Selective inhibition of growth of tuberous sclerosis complex 2\u2013null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR\/S6 kinase activity","volume":"67","author":"Finlay","year":"2007","journal-title":"Cancer Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1158\/1535-7163.MCT-09-0055","article-title":"Renal and liver tumors in Tsc2+\/- mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor","volume":"8","author":"Finlay","year":"2009","journal-title":"Mol Cancer Therap."},{"key":"B90","doi-asserted-by":"publisher","first-page":"154ra34","DOI":"10.1126\/scitranslmed.3003840","article-title":"Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary Lymphangioleiomyomatosis (LAM)","volume":"4","author":"Goncharova","year":"2012","journal-title":"Sci Transl Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"9902","DOI":"10.1073\/pnas.0811321106","article-title":"mTOR complex 2 in adipose tissue negatively controls whole-body growth","volume":"106","author":"Cybulski","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B92","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1146\/annurev.genet.40.051206.105231","article-title":"Surviving the breakup: the DNA damage checkpoint","volume":"40","author":"Harrison","year":"2006","journal-title":"Annu Rev Genet."},{"key":"B93","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","article-title":"Targeting WEE1 kinase in cancer","volume":"37","author":"Matheson","year":"2016","journal-title":"Trends Pharmacol Sci."},{"key":"B94","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1038\/s41467-018-05639-x","article-title":"Systems biology approach reveals a link between mTORC1 and G2\/M DNA damage checkpoint recovery","volume":"9","author":"Hsieh","year":"2018","journal-title":"Nat Commun."},{"key":"B95","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1083\/jcb.200812045","article-title":"The decision to enter mitosis: feedback and redundancy in the mitotic entry network","volume":"185","author":"Lindqvist","year":"2009","journal-title":"J Cell Biol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"109185","DOI":"10.1016\/j.biopha.2019.109185","article-title":"Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer","volume":"117","author":"Liu","year":"2019","journal-title":"Biomed Pharmacother."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1200\/JCO.19.00730","article-title":"Dose escalation trial of the wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer","volume":"37","author":"Cuneo","year":"2019","journal-title":"J Clin Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1900329","DOI":"10.1183\/13993003.00329-2019","article-title":"A genome-wide association study implicates NR2F2 in lymphangioleiomyomatosis pathogenesis","volume":"53","author":"Kim","year":"2019","journal-title":"European Resp J."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1900863","DOI":"10.1183\/13993003.00863-2019","article-title":"The discovery of novel mechanisms for lymphangioleiomyomatosis pathogenesis through GWAS: a rarity in rare respiratory disorders","volume":"53","author":"Kristof","year":"2019","journal-title":"Eur Respiratory Soc"},{"key":"B100","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/aps.2014.86","article-title":"The role of the orphan nuclear receptor COUP-TFII in tumorigenesis","volume":"36","author":"Xu","year":"2015","journal-title":"Acta Pharmacol Sin."},{"key":"B101","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1349-7006.2008.01078.x","article-title":"Chicken ovalbumin upstream promoter transcription factor II in human breast carcinoma: possible regulator of lymphangiogenesis via vascular endothelial growth factor-C expression","volume":"100","author":"Nagasaki","year":"2009","journal-title":"Cancer Sci."},{"key":"B102","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1535-6108(03)00187-9","article-title":"TSC2 regulates VEGF through mTOR-dependent and -independent pathways","volume":"4","author":"Brugarolas","year":"2003","journal-title":"Cancer Cell."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yexcr.2006.09.009","article-title":"Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate","volume":"313","author":"Diez","year":"2007","journal-title":"Exp Cell Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"10188","DOI":"10.1158\/0008-5472.CAN-05-3937","article-title":"Decreased chicken ovalbumin upstream promoter transcription factor ii expression in tamoxifen-resistant breast cancer cells","volume":"66","author":"Riggs","year":"2006","journal-title":"Cancer Res."},{"key":"B105","doi-asserted-by":"publisher","first-page":"e47451","DOI":"10.15252\/embr.201847451","article-title":"Oncogenic KRAS signaling activates mTORC1 through COUP-TFII-mediated lactate production","volume":"20","author":"Byun","year":"2019","journal-title":"EMBO Rep."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.554134\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T06:56:22Z","timestamp":1600930582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.554134\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":105,"alternative-id":["10.3389\/fmed.2020.554134"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.554134","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]},"article-number":"554134"}}